Showing results (21-30 of 70) with videos related to
Sort By:
Pageof 7
The American Journal of Cardiology|October 23, 1985
Effects of esmolol on cardiac function: evaluation by noninvasive techniquesA S Iskandrian, A H Hakki, A LadduAmerican Heart Journal|September 1, 1991
Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse eventsJ C Somberg, R Achari, A R LadduJournal of Clinical Pharmacology|October 12, 2000
The relationship between terazosin dose and blood pressure response in hypertensive patientsR Achari, B Hosmane, E Bonacci, et al.European Urology|January 1, 1992
Efficacy of terazosin in patients with benign prostatic hyperplasiaH Matzkin, M S Soloway, M C Rangel, et al.Biopharmaceutics & Drug Disposition|January 1, 1984
The influence of vitamin C on antipyrine pharmacokinetics in elderly menJ Blanchard, R Achari, G G Harrison, et al.Scientific Reports|February 14, 2023
Diagnosis of Fusarium oxysporum f. sp. ciceris causing Fusarium wilt of chickpea using loop-mediated isothermal amplification (LAMP) and conventional end-point PCRSaidi R Achari, Ross C Mann, Mamta Sharma, et al.British Journal of Clinical Pharmacology|December 1, 1985
Pharmacokinetics of flestolol in man: preliminary dataR Achari, J D Hulse, D Drissel, et al.Journal of Clinical Pharmacology|January 1, 1986
Metabolism and urinary excretion of esmolol in humansR Achari, D Drissel, W L Matier, et al.Journal of Clinical Pharmacology|May 1, 1992
Effect of age and dose on the incidence of adverse events in the treatment of hypertension in patients receiving terazosinB S Hosmane, C J Maurath, D C Jordan, et al.American Heart Journal|October 1, 1987
Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settingsP Turlapaty, A Laddu, V S Murthy, et al.Pageof 7